Le Lézard
Classified in: Health
Subject: MRR

Antiemetic Drug Market size is to grow by USD 1.63 billion, The increasing healthcare expenditure to boost market growth, Technavio

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- The antiemetics drugs market size is estimated to grow by USD 1.63 billion at a CAGR of 6.47% between 2022 and 2027.  The increasing healthcare expenditure is a key factor driving market growth. Global health spending rises due to factors like population growth, aging demographics, and technological advancements, driving demand for healthcare services. Increased access to medical care fuels demand for antiepileptic drugs and antiemetics as individuals seek treatment for various conditions. Government initiatives and insurance programs further boost healthcare accessibility, contributing to the growing demand for medicinal products. For Comprehensive details on the market size of the historical period(2017 to 2021) and forecast period (2023-2027) - View the Free Sample report

Report Coverage


Page number


Base year


Historic period


Forecast period


Growth momentum & CAGR

Accelerate at a CAGR of 6.47%

Market growth 2023-2027

USD 1.63 billion

Market structure


YoY growth (%)


Regional analysis

APAC, Europe, North America, South America, and Middle East and Africa

Performing market contribution

North America at 37%

Key countries

US, China, Japan, UK, and Germany

Vendor Landscape

The antiemetic drug market is fragmented; the vendors are competing with competitors and are trying to get greater market share. The market is growing, and the chances of new entrants cannot be overlooked. The major vendors have well-established economies of scale and market presence and generally rely on positioning technological advances, and the price of the products -The report provides a full list of key vendors, their strategies, and the latest developments. Buy Now

Primary Trend: Rising Demand in Emerging Economies

Emerging economies are experiencing a rising awareness of healthcare alongside greater accessibility to medical services.

Formidable Entry Barriers Pose Significant Challenges to Market Growth

The larger companies boast extensive distribution channels and collaborate with major hospitals and health centers. Technavio has identified key trends, drivers, and challenges in the market, which will help clients improve their strategies to stay ahead of their competitors. - View a Free Sample Report

Company Profiles

The antiemetic drug market report includes information on the product launches, sustainability, and prospects of leading vendors including Algen Healthcare Ltd., Boehringer Ingelheim International GmbH, Bristol Laboratories Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Eagle Pharmaceuticals Inc., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., RedHill Biopharma Ltd., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Competitive Analysis

The report includes competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and market performance score. The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others Download a Free Sample Report

Market Segmentation

By Application, the market is classified into Chemotherapy, Surgery, Gastroenteritis, and Others. The market share growth by the chemotherapy segment will be significant during the forecast period. Chemotherapy effectively targets cancer cells but can harm healthy cells, causing nausea and vomiting. Antiemetic therapy aims to manage these side effects, enabling patients to undergo chemotherapy smoothly. Combining various antiemetic drugs helps control nausea and vomiting. Increasing cancer cases worldwide will drive chemotherapy demand, spurring market growth.

By Geography, the market is classified as North America, Europe, Asia, and the Rest of the World (ROW). North America is estimated to contribute 37% to the growth of the global market during the forecast period. North America, encompassing nations like the US, Canada, and Mexico, stands as a crucial region for the advancement, production, and usage of antiemetic medications, propelling regional market expansion. Numerous prominent pharmaceutical firms based in the region focus on creating and producing antiepileptic treatments. They heavily invest in R&D to unveil novel drugs boasting enhanced effectiveness and safety characteristics. Subscribe Now

Analyst Review

The Antiemetic Drug Market is driven by the demand for medications targeting specific receptors such as D2 Receptors, 5HT-3 Receptors, MI Receptors, and HI Receptors. These drugs are used to treat various conditions like Chemotherapy-induced nausea and vomiting, Motion Sickness, Gastroenteritis, and Dizziness, among others. They are available in different forms, including Prescription drugs and Over-the-counter (OTC) drugs.

Research and development activities focus on identifying new drug targets, especially in the context of ailments like Cancer and Gastroenteritis. Adverse effects of chemotherapy and the global cancer burden have led to an increased demand for antiemetics, particularly in developing nations. The healthcare sector is witnessing a surge in the use of Prokinetics, Serotonin Antagonists, Antimuscarinics, Antihistaminic, and Neurokinin Antagonists to address these issues, highlighting the importance of effective antiemetic drugs in patient care.

Overall, the market for antiemetic drugs plays a crucial role in managing symptoms such as Nausea, Vomiting, and Emesis across various medical conditions, including Pregnancy, Food Poisoning, and Vertigo. These drugs continue to be essential in providing relief from these distressing symptoms and improving the quality of life for patients. Download a Sample Report

Related Reports

The Gastroparesis Drugs Market size is estimated to grow by USD 1.42 billion at a CAGR of 3.69% between 2023 and 2028. 

The global vertigo drugs market size is estimated to grow by USD 551.42 million at a CAGR of 5.58% between 2022 and 2027. 


Excustive Summary

Market Landscape

Market Sizing

Historic Market Sizes

Five Forces Analysis

Market Segmentation by Application

Market Segmentation by Drug Class

Market Segmentation by Geography

Customer Landscape

Geographic Landscape

Drivers, Challenges, & Trends

Company Landscape

Company Analysis


About US

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

These press releases may also interest you

at 13:00
Starting next week, the Network of National Library of Medicine and Columbus Metropolitan Library in Columbus, OH will host the All of Us Journey. This traveling educational exhibit brings the National Institutes of Health's All of Us Research...

at 13:00
$56.5M Equity Financing Led by Questa Capital, Laerdal Million Lives Fund, and Catalyst Health Ventures, with New Participation from RC Capital and Eckuity CapitalAvive has rapidly built an expansive and diverse customer base, delivering its FDA...

at 13:00
Lynx Dx, a leader in innovative diagnostic solutions, hailed new peer-reviewed research published today in the Journal of the American Medical Association (JAMA) Oncology that validates the efficacy of MyProstateScore 2.0 (MPS2), the company's...

at 12:50
Data infrastructure and analytics company Kalderos, Inc., today announced that on Tuesday, April 16, it asked the Eighth Circuit for leave to file an amicus brief in support of Pharmaceutical Research and Manufacturers of America's (PhRMA's) petition...

at 12:20
Titan CEO and headline sponsor Wipfli LLP are pleased to announce Judith Nowlin, CEO of Nest Collaborative as a 2024 Colorado Titan 100. The Titan 100 program recognizes Colorado's Top 100 CEOs & C-level executives. They are the area's most...

at 12:18
Memorial Healthcare System and Solis Mammography, are pleased to announce the opening of the collaboration's first community-based breast screening centers in Weston, Plantation and Hialeah, Florida. The centers represent the commitment that both...

News published on and distributed by: